- Published at
- by gurufocus.com
mixed
mixed
News for Innate Pharma S.A. (IPHYF)
- Published at
- by gurufocus.com
mixedmixedInnate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
\nRegulatory News:\n\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â\u0080\u009cInnateâ\u0080\u009d or the â\u0080\u009cCompanyâ\u0080\u009d) today announced it will propose to its Annual Genera- Published at
- by gurufocus.com
mixedmixedInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
\nRegulatory News: \n\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â\u0080\u009cInnateâ\u0080\u009d or the â\u0080\u009cCompanyâ\u0080\u009d) will hold its annual general meeting of shareholder- Published at
- by gurufocus.com
mixedmixedInnate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced that members of its executive team w- Published at
- by insidermonkey.com
mixedmixedInnate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Innate Pharma Full Year 2024 Financial Results and Business Update. All lines have been placed on mute to prevent any background noise.- Published at
- by seekingalpha.com
neutralneutralInnate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ETCompany ParticipantsHenry Wheeler - VP, IR and...- Published at
- by gurufocus.com
mixedmixedInnate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced that members of its executive team a- Published at
- by gurufocus.com
mixedmixedInnate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”), today announces that the Company will hold a confer- Published at
- by gurufocus.com
mixedmixedInnate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced that members of its executive team- Published at
- by benzinga.com
mixedmixedWhy Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Allurion Technologies (NYSE:ALUR), Aclarion (NASDAQ:ACON)
Shares of Logility Supply Chain Solutions, Inc. LGTY rose sharply in today's pre-market trading after Aptean announced an agreement to acquire Logility in a $14...- Published at
- by investing.com
mixedmixedInnate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors By Investing.com
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors- Published at
- by investing.com
mixedmixed- Published at
- by gurufocus.com
mixedmixedNumber of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Regulatory News: Pursuant to the article L. 233-8 II of the French ”Code de Commerce” and the article 223-16 of the French stock-market authorities (Auto- Published at
- by gurufocus.com
mixedmixedInnate Pharma Announces Transformative Strategy to Accelerate Growth
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced its updated strategy for company gr- Published at
- by benzinga.com
mixedmixedWhy Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - AtlasClear Holdings (AMEX:ATCH), Akoustis Technologies (NASDAQ:AKTS)
Shares of Edgewise Therapeutics, Inc. EWTX rose sharply in today's pre-market trading after the company reported topline results from Phase 2 CANYON trial of Se...- Published at
- by investing.com
mixedmixedInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma By Investing.com
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma- Published at
- by investing.com
mixedmixedInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma By Investing.com
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma- Published at
- by gurufocus.com
mixedmixedInnate Pharma Releases Its 2025 Financial Calendar
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today released its 2025 financial calendar: Marc- Published at
- by investing.com
mixedmixedInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET ® IPH6501 By Investing.com
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET ® IPH6501- Published at
- by benzinga.com
mixedmixedBoeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday - Boeing (NYSE:BA)
With U.S. stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expect...